Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays
04:30pm, Tuesday, 18'th May 2021
SAN CARLOS, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ
Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma
04:35pm, Wednesday, 12'th May 2021
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up
Iovance (IOVA) Q1 Earnings Miss Estimates, Pipeline in Focus
09:46am, Friday, 07'th May 2021
Iovance's (IOVA) first-quarter earnings lag estimates. The company is progressing well in terms of development of its lead pipeline candidate.
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2021 Results - Earnings Call Transcript
08:53pm, Thursday, 06'th May 2021
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2021 Results - Earnings Call Transcript
Iovance Biotherapeutics to Present at Upcoming Conferences
04:30pm, Tuesday, 04'th May 2021
SAN CARLOS, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
10:50am, Wednesday, 28'th Apr 2021
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study
Iovance Biotherapeutics: The Frontier Of Novel Cancer Treatment
07:16am, Wednesday, 21'st Apr 2021
Buying stocks in a bear market necessitates courage, as you need to overcome your fear. Conquering your fear to purchase during a down cycle usually leads to outsized returns.
Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study
Eli Lilly, Bristol-Myers and Iovance Await Important Drug Trial Results
02:58pm, Tuesday, 16'th Mar 2021
The prospects for several drug makers—and their investors—are likely to be affected as clinical trial results for key medications are reported this year.
Revisiting Iovance Biotherapeutics After The Dip
05:36pm, Monday, 15'th Mar 2021
Today, we revisit oncology concern Iovance Biotherapeutics for the first time in years after a recent dip in its share price.
SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Bumble, NextEra Energy, Wheaton Precious Metals and More Monday Afternoon Analyst Calls
12:20pm, Monday, 08'th Mar 2021
With the trading day about halfway over, the broad markets were pushing higher on the day.
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
04:01pm, Monday, 01'st Mar 2021
SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance (IOVA) Q4 Earnings Miss Estimates, Pipeline in Focus
11:22am, Friday, 26'th Feb 2021
Iovance's (IOVA) fourth-quarter earnings miss estimates. The company is progressing well with development of its lead pipeline candidate.
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2020 Results - Earnings Call Transcript
11:36pm, Thursday, 25'th Feb 2021
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2020 Results - Earnings Call Transcript
